Introduction About 90% of cases of Parkinson's disease (PD) are idiopathic and attempts to understand pathogenesis typically assume a multifactorial origin. Multifactorial diseases can be studied using metabolomics, since the cellular metabolome reflects the interplay between genes and environment. Objective The aim of our case-control study is to compare metabolomic profiles of whole blood obtained from treated PD patients, de-novo PD patients and controls, and to study the perturbations correlated with disease duration, disease stage and motor impairment. Methods We collected blood samples from 16 drug naïve parkinsonian patients, 84 treated parkinsonian patients, and 42 age matched healthy controls. Metabolomic profiles have been obtained using gas chromatography coupled to mass spectrometry. Multivariate statistical analysis has been performed using supervised models; partial least square discriminant analysis and partial least square regression. Results This approach allowed separation between discrete classes and stratification of treated patients according to continuous variables (disease duration, disease stage, motor score). Analysis of single metabolites and their related metabolic pathways revealed unexpected possible perturbations related to PD and underscored existing mechanisms that correlated with disease onset, stage, duration, motor score and pharmacological treatment. Conclusion Metabolomics can be useful in pathogenetic studies and biomarker discovery. The latter needs large-scale validation and comparison with other neurodegenerative conditions.
sporadic, and only 10% of cases are familiar. Thirty percent of the latter are monogenic forms (Klein and Westenberger 2012) . Like many diseases, onset of PD is likely determined by the interplay of a genetic predisposition and environmental factors (Kalia and Lang 2015; Lill 2016; Noyce et al. 2012) . Several pathogenetic models have been described regarding the mechanisms of dopamine neuron degenerations using monogenic forms as models. They involve protein misfolding (Bertoncini et al. 2005) , impairment of the ubiquitin proteasome pathway of protein degradation (Chakraborty et al. 2017) , impairment of lysosomal proteolysis (Mazzulli et al. 2011) , mitochondrial dysfunction (Hu and Wang 2016) , and oxidative stress (Manoharan et al. 2016) .
New insights about the pathogenesis of PD can be obtained through the use of untargeted metabolomics. Metabolomics is the study of the entire set of metabolites, small molecules with a molecular weight less than 1.5 kDa, in a biological system (D'Alessandro et al. 2012) . Untargeted metabolomics, like the other -omic sciences (genomics, trancsriptomics, proteomics) , allows the characterization of a biological system without a pre-formed hypothesis; however, unlike the other-omic sciences, it can be useful in the characterization of multifactorial diseases because it reflects the interaction between genes and environment (Dunn et al. 2011) .
Untargeted metabolomic studies have already been performed in PD in order to look for biomarkers of disease. A urinary metabolomic study obtained a differential signature of parkinsonian patients and controls, finding metabolites whose concentrations were correlated with disease stage (Luan et al. 2015) . A study performed on plasma obtained a separate fingerprint of treated and drug-naïve patients compared to controls (Bogdanov et al. 2008) . A further study performed on serum revealed different metabolomic signatures between slow and rapid motor progressors (Roede et al. 2013) . Serum metabolomics has also differentiated parkinsonian patients with and without dementia (Han et al. 2017) . A longitudinal study was performed on plasma and cerebrospinal fluid involving drug-naïve patients in which metabolomic profiles were obtained at baseline and after two years, in order to study disease progression without drug interference (LeWitt et al. 2017) . Cerebrospinal fluid metabolomics has also been performed in order to obtain a signature of early stage PD (Trezzi et al. 2017) . Moreover, a fingerprint involving patients with LRRK2 mutation was performed in order to reveal preclinical metabolomic perturbations in asymptomatic patients carrying genetic mutations (Johansen et al. 2009 ). Metabolomics has also been applied on murine models of PD: a study performed on transgenic mice carrying the A53T α-synuclein mutation found important modifications in guanosine metabolism (Chen et al. 2015) .
The aim of our study is to compare metabolomic profiles of whole-blood obtained from treated PD patients, de novo (i.e. drug-naïve) PD patients and controls. In addition, we seek to study the influence of comprehensive disease variables (duration, stage, motor impairment and pharmacological treatment) on the metabolome itself. Such comparisons have not been reported in the literature.
Materials and methods

Subjects
We enrolled 107 PD patients, of which 84 were treated and 23 were de novo, and 42 controls among their spouses, after receiving written informed consent. Patients were enrolled at the University Centers for movement disorders of Naples and Salerno (Italy). Human tissue collection strictly adhered to the guidelines outlined in the Declaration of Helsinki (World Medical Association 2013). The study was approved by the local institutional ethics committee Comitato Etico Campania Centro, n. 354/16. Eighty four consecutive treated PD patients and 23 consecutive de novo patients were enrolled on the basis of a clinical diagnosis of PD according to the UK Brain Bank criteria (Hughes et al. 1992) . The 23 consecutive de novo patients were enrolled among those performing a [ 123 I]FP-CIT SPECT exam for dopamine transporter assessment. Of the 23 patients enrolled, 7 were excluded because they did not have a SPECT pattern of nigro-striatal degeneration.
Anamnestic and clinical assessment
For each patient and control, data regarding age, weight, height, waist circumference, present or past occupation, and pharmaceutical treatments were collected. For each patient, disease history, unified Parkinson's disease rating scale (UPDRS part III) score and modified Hoehn and Yahr (H&Y) scale score were collected.
Blood collection
Blood samples were collected by venipuncture into a BD Vacutainer ® red tube, without additives, and frozen at −20 °C until transfer to the metabolomics laboratory. The −20 °C storage time was less than 2 weeks, after which the samples were stored at −80 °C until analysis. All patients were asked to respect a 12-h fast before blood collection.
Untargeted metabolomics analysis
Metabolite extraction and derivatization
Metabolome extraction, purification and derivatization was carried out with the MetaboPrep GC kit (Theoreo srl, Montecorvino Pugliano [SA], Italy) according to the manufacturer's instructions (details are reported in Supplementary S1). Because this study used whole blood samples (no centrifugation; no clotting additives), the metabolomes that were obtained derive from the entire suite of metabolites present in each subject's blood at the moment of sampling.
GC-MS analysis
Two µL samples of the derivatized solution were injected into the GC-MS system (GC-2010 Plus gas chromatograph coupled to a 2010 Plus single quadrupole mass spectrometer; Shimadzu Corp., Kyoto, Japan). Chromatographic separation was achieved with a 30 m 0.25 mm CP-Sil 8 CB fused silica capillary GC column with 1.00 µm film thickness from Agilent (Agilent, J&W Scientific, Folsom, CA, USA), with helium as carrier gas. The initial oven temperature of 100 °C was maintained for 1 min and then raised by 4 °C/ min to 320 °C with a further 4 min of hold time. The gas flow was set to obtain a constant linear velocity of 39 cm/s and the split flow was set at 1:5. The mass spectrometer was operated in electron impact (70 eV) in full scan mode in the interval of 35-600 m/z with a scan velocity of 3333 amu/s and a solvent cut time of 4.5 min. The complete GC temperature program duration was 60 min. Untargeted metabolites were identified by comparing the mass spectrum of each peak with the NIST library collection (NIST, Gaithersburg, MD, USA). Metabolic profiles were integrated to obtain the area under each peck using the software GCMS Solution v. 2.72 (details can be found in the supplement S1).
Over 250 signals per blood sample were produced, although several were not investigated further because they were not consistently found in other sets of samples or could not be confirmed as metabolites due to poor spectral quality resulting from low abundance. A total of 196 endogenous metabolites involved in energy metabolism, lipid metabolism and amino acid metabolism were detected consistently. To identify peaks, the linear index difference max tolerance was set at 10, while the minimum matching for the NIST library search was set at 85%. Selected metabolites were further confirmed using independent analytical standards as requested by the "Metabolomics Standards Initiative" (Sumner et al. 2007 ) (MSI Level = 1). Results were summarized in a comma-separated matrix file and loaded in the appropriate software for statistics manipulation (see below).
Statistical analysis
Demographical and clinical data
Statistical analysis was performed using Statistica software (StatSoft, Oklahoma, USA) and Minitab (Minitab Inc, Pennsylvania, USA). Normal distribution of data was verified using the Kolmogorov-Smirnov test. Since the data were not normally distributed, we used Kruskal-Wallis test by ranks (one-way ANOVA on ranks) with the Conover-Iman post hoc test for inter-group comparisons with p value < 0.05 being considered statistically significant. Data were reported as median and inter quartile range.
Multivariate data analysis
Partial least square discriminant analysis (PLS-DA) was performed on Internal Standard peak area normalized chromatograms (Sysi-Aho et al. 2007) using R (Foundation for Statistical Computing, Vienna, Austria). Mean centering and unit variance scaling was applied for all analyses. Class separation was achieved by PLS-DA, which is a supervised method that uses multivariate regression techniques to extract, via linear combinations of original variables (X), the information that can predict class membership (Y). In addition, PLS regression was performed using the plsr function included in the R pls package (Mevik and Wehrens 2007) . Classification and cross-validation was performed using the corresponding wrapper function included in the caret package (Kuhn 2008) . A permutation test was performed to assess the significance of class discrimination. In each permutation, a PLS-DA model was built between the data (X) and the permuted class labels (Y) using the optimal number of components determined by cross validation for the model based on the original class assignment. Two types of test statistics were used to measure class discrimination. The first is based on prediction accuracy during training. The second made use of separation distance based on the ratio Between group sum of the squares and the Within group sum of squares (B/W-ratio). If the observed test statistic was part of the distribution based on the permuted class assignments, class discrimination cannot be considered significant from a statistical point of view (Bijlsma et al. 2006) . Variable Importance in Projection (VIP) scores were also calculated for each metabolite. A VIP-score is a weighted sum of squares of the PLS loadings, taking into account the amount of explained Y-variation in each dimension.
Metabolites that show a VIP score higher than the cut off value (≥ 1.5) were considered in detail as these metabolites are statistically most responsible for class separation. UpsetR package (Lex et al. 2014 ) was used to evaluate the simultaneous presence of the VIP-metabolites in several models.
The metabolic pathway was constructed using MetScape application (Karnovsky et al. 2012 ) of the software Cytoscape (Nishida et al. 2014) . To identify changes in metabolite levels associated with continuous variables (UPDRS-III score, H&Y stage, disease duration), we carried out partial least squares regression (PLS-R) analyses, with the continuous variables as the dependent variables.
Results
The demographic and clinical characteristics of cases and controls are reported in Table 1 . These characteristics were similar in the three groups (Treated [T], drug-naïve [DN] and controls (i.e. healthy subjects) [HS] ). Height in treated patients seemed to be greater compared with controls, but this difference is not significant if the p-value was adjusted according to Bonferroni.
As shown in Fig. 1 A1 , the PLS-DA score plots clearly differentiated between the DN and HS groups. The 13 highest scoring VIP metabolites identified by PLS-DA are shown in Fig. 1A2 . These metabolites were selected by setting the VIP-score > 1.5 as a cut-off value for significance.
The PLS-DA model also discriminated the T and HS groups with little overlap (Fig. 1B1) . Fifteen metabolites have a VIP-score > 1.5 (Fig. 1B2) .
A third PLS-DA model ( Fig. 1C1 ) separated PD subjects according to presence (T) or absence (DN) of drug treatment, 7 metabolites had a VIP-score > 1.5 (Fig. 1C2) . A three class PLS-DA model was also built and showed a good separation between the DN, T and HS groups (Fig. 1D) . Models cross validation and permutation test results are reported in Supplementary S2.
Although the male/female ratio was different between T and HS (p < 0.001) the PLS-DA models are not affected by this difference. The gender related correctness and errors of classification (in terms of true positive/negative and false positive/negative cross validation results) were evaluated by means of a Chi Square test using p < 0.05 as significance level. No differences were observed in the male/ female ratio regarding the classification accuracy of the investigated classes (see Supplementary Tables TS3-TS5) .
As shown in Fig. 1 , butanoic and glutamic acid were selected as significant VIPs in all three PLS-DA models, while nicotinic acid and threitol by two models (DN Vs HS and T Vs DN). Table 2 reports the fold change and the significance of all metabolites with VIP-score > 1.5.
The metabolic pathway analysis of the selected metabolites (VIP) is summarized in the metabolic systems map shown in Fig. 2 . There is a definite interplay of several pathways involving: Arachidonic acid metabolism, Bile acid biosynthesis, Butanoate metabolism, C21-steroid hormone biosynthesis and metabolism, De novo fatty acid biosynthesis, Fructose and mannose metabolism, Galactose metabolism, Glycerophospholipid metabolism, Glycine, serine, alanine and threonine metabolism, Glycosphingolipid metabolism, Lysine metabolism, Methionine and cysteine metabolism, Phosphatidylinositol phosphate metabolism, Prostaglandin formation from arachidonate, Purine metabolism, Pyrimidine metabolism, Saturated fatty acids beta-oxidation, Squalene and cholesterol biosynthesis, TCA cycle, Tryptophan metabolism, Tyrosine metabolism, Urea cycle and metabolism of arginine, proline, glutamate, aspartate and asparagine, Valine, leucine and isoleucine degradation, Vitamin B3 (nicotinate and nicotinamide) metabolism, Vitamin B9 (folate) metabolism. Partial least square regressions were calculated to determine the degree of correlation between blood metabolite profiles and continuous variables of treated patients (UPDRS-III and H&Y score) and of all patients (disease duration). The regressions selected eight, eight and seven metabolites respectively with a VIP score > 1.5, as shown in Table 3 . The absolute value of each Figure 3 shows the metabolites with a VIP score > 1.5 in the various classifications. In particular, butanoic acid has a VIP-score > 1.5 in 4 PLS models, while isocitric acid, serine, urea, glutamic and nicotinic acid in 3 models.
Discussion
Our study assessed the metabolomic profiles of PD patients and controls in an effort to identify the main variables that may influence those profiles. Identification of the various metabolites most responsible for class separations in our statistical models, and the corresponding metabolic pathway analysis, may contribute to the understanding of the biochemical impairments involved in PD.
However, stratification of patients according to disease variables (duration, stage, motor score, pharmacological treatment) is essential to better appreciate the importance of such variables on the biochemical impairment itself.
Metabolomic profiles of patients and controls, obtained on whole blood samples analyzed with gas chromatography coupled to mass spectrometry, allowed the training of a mathematical model able to generate the most significant linear combinations of metabolites responsible for separation among pre-imposed classes. Metabolites having the highest statistical influence on separation (i.e. those with VIP score > 1.5) are called "VIP metabolites".
VIP metabolites can be considered as the "final actors" of an event cascade, triggered by a particular enzymatic activity deficiency, possibly originating in some other pathway. Indeed, an enzymatic activity deficiency, causing substrate accumulation and product deficiency, could be compensated by other reactions involved in other pathways which share the same substrates and/or products. Thus, the effect of an enzymatic activity deficiency could be detected far from the main involved pathway itself. For this reason, the aim of our pathway analysis was to identify the shortest metabolic routes connecting our VIP metabolites.
The study of the most relevant metabolites and the pathways in which they are involved may offer new insights regarding the pathogenesis of Parkinson's disease and suggest new biomarkers. For example, leucine was selected as VIP in the PLS-DA model comparing de novo patients versus controls; blood concentrations in de novo patients are higher with respect to controls (see Table 2 ). Leucine is described in the literature as activating the mTORC1 pathway, thereby blocking autophagy (Shafei et al. 2017) . Autophagy inhibition may contribute to the accumulation and aggregation of proteins (such as α-synuclein) such as observed in PD cases (Lan et al. 2017) . Moreover, there is a negative trend in hypoxanthine concentration in de novo patients with respect to controls. Similar results have been obtained from drug-naïve patients in a metabolomic analysis performed on plasma (Johansen et al. 2009 ). Also, glutamic acid has been selected as VIP in 3 models (DN vs HS, DN vs. T, T vs. HS). Impairment of glutamic acid homeostasis in PD may originate from glutammatergic projections stemming from cortex, thalamus and peduncolopontine nucleus towards subtalamic nucleus. This impairment may explain the beneficial effects of N-methyl-d-aspartate receptor (NMDA) receptor antagonists on experimental models of parkinsonism, the use of which may block the abovementioned circuits (DeLong and Wichmann 2015) . There is also a decrease in ɣ-amino butyric acid (GABA) concentrations in de novo patients with respect to controls. Gabaergic impairment has been recently hypothesized as being implicated in parkinsonian neurodegeneration, prodromes of disease, motor signs and cognitive decline (Błaszczyk 2016) . Kynurenine and xanthurenic acid are both tryptophan metabolites. The kynurenine pathway generates oxidized nicotine adenine dinucleotide (NAD +) from tryptophan degradation (Lim et al. 2017 ). These two molecules, selected as VIPs in the separation between treated patients and controls, also showed a trend of increase in de novo patients compared to controls according to Widner et al. (2002) , resulting from an increase in tryptophan degradation in PD pathogenesis. Serine has been selected has VIP in the DN vs. HS, H&Y and UPDRSIII models. A study by LeWitt et al. (2017) found plasma serine to be one of the best predictors of motor severity. Serine interaction with NMDA receptors, causing excitotoxicity, has been described by Katsuki et al. (2004) . Serine is also involved in glutathione biosynthesis (Meiser et al. 2016) . In turn, the increased plasma glutathione levels observed in parkinsonian patients has been correlated to an increased response to oxidative stress (Bogdanov et al. 2008) . Pathway analysis showed the impairment of glycosphingolipids. It is well known that a mutation in the heterozygous glucocerebrosidase (GBA) gene represents a risk factor for the development of Parkinson's disease (Asselta et al. 2014) . Furthermore, the specific impairment of arachidonic acid metabolism, phosphatidylinositol phosphate metabolism and prostaglandin formation from arachidonate in the separation between treated patients and controls (see also Fig. 3 ) may be related to the role of neuroinflammation in neurodegeneration (Kempuraj et al. 2016) , which may, in turn, play an important role in disease progression. Also, as far as branched-chain amino-acid pathway is concerned, their deficiency has been associated with muscle wasting and tremor (Molina et al. 1997) .
Regarding metabolites correlated to disease variables, butanoic acid was selected as VIP in the DN Vs HS, DN Vs T, T Vs HS and H&Y PLS models. This result indicates that butanoic acid is probably involved in PD development. On the contrary, isocitric acid was selected as VIP in Disease duration, H&Y and T Vs HS PLS models and urea was selected as VIP in H&Y, T versus HS and UPDRSIII models: these results suggest that these metabolites can be considered indicators of disease progression. Butanoic acid is a small chain fatty acid (SCFA), produced by the gut microbiota. Nowadays, the existence of a gut microbiota-brain axis (GMBA), providing a bidirectional homeostatic route of communication that uses neural, hormonal and immunological routes, is well established, and the dysfunction of this axis can have pathophysiological consequences (Mayer 2011) . Several studies (Bourassa et al. 2016; Parashar and Udayabanu 2017; Sampson et al. 2016) have highlighted the role of the GMBA in Parkinson's disease, starting from the observation of a gastro enteric involvement in PD. The metabolomics signature of PD and PD related characteristics we have herein described is highly influenced by microbiota metabolites such as butanoic, propionic and nicotinic acid, and GABA. Butanoic acid has a histone acetylation activity. Several studies have shown that butanoic acid can protect neurons from cell death in models of Parkinson's disease (Kidd and Schneider 2010; Sharma et al. 2015; St Laurent et al. 2013 ). On the contrary, Sampson et al. (2016) have recently demonstrated in α-Synuclein overexpressing transgenic (ASO) mice that SCFAs are sufficient to promote α-synuclein mediated neuroinflammation. Indeed, they treated germ free ASO mice and germ-free wild type animals with a mixture of SCFAs (acetate, propionate, and butyrate) observing microglia increased activation in SCFA-administered animals, compared to untreated mice. Moreover, microglia from germ free-ASO mice fed with SCFAs was significantly larger in diameter than that of germ-free wild type animals treated with SCFAs, with a concomitant decrease in the length and total number of branches. This indicates that the role of SCFA and the gut microbiota disbyosis are crucially involved in the pathogenesis and in the progression of PD, even though their role is still not clear. Moreover, homovanillic acid and 3-metoxy tyrosine were selected in the DN versus T model. They are both dopamine and levodopa metabolites. Stratification of patients according to disease duration and the related progression confirmed the importance of these metabolites. This result may be correlated to the increase of levodopa abundances in parkinsonian patients over the years. A metabolomic study performed on serum revealed that levels of 3-methoxy tyrosine in parkinsonian patients correlates with levodopa concentrations (Hatano et al. 2016) .
Untargeted metabolomics produces a wealth of information that has to be carefully managed to avoid incorrect pathophysiological interpretations.
Concluding, the main result of our study is that a metabolomic fingerprint of PD is obtainable and could, in the future, represent a new frontier in the diagnosis of this condition. However, our study demonstrates that this metabolomic fingerprint is influenced by several variables that must be carefully taken into consideration when looking for a diseasespecific metabolomic fingerprint. Taking into account all disease variables (such as pharmaceutical treatment, motor score, disease duration and stage) is of crucial importance when looking for disease specific profiles.
One limitation of our study is the lack of an adequate cohort of control constituted by other neurodegenerative diseases, in order to distinguish which metabolites and pathways are specific for Parkinson's disease. Although the principal aim of our pilot study is not to identify validated biomarkers for PD, but just to show the possible roles of disease characteristics and pharmacological treatments in this complex selection, further and independent studies are needed to validate our results (Trezzi et al. 2018) . Also, given the pilot nature of our study, we were unable to exclude the effects of concomitant conditions on metabolomic profiles.
